We’re pleased to announce the completion of our first home healthcare visits using mobile nurses in China. 

This achievement underscores our commitment to enhancing healthcare delivery and patient outcomes by enabling patient access to clinical trials globally.  

The home healthcare visits are part of an ongoing Phase 2 clinical trial to evaluate safety and efficacy of a new therapeutic for treatment of a rare genetic musculoskeletal disorder.   

The clinical trial encompasses participants across various regions in China, collaborating with esteemed healthcare professionals and organizations to ensure excellence in care. Home healthcare visits are conducted by trained healthcare providers, ensuring that patients receive the best possible care within the comfort and safety of their own homes.  

In aligning with our dedication to ensuring the highest standards of patient care and data security, our operations are supported by a proprietary data capture platform and process designed to meet China’s regulatory requirements for data privacy, allowing real-time e-data collection during the home visit.   

Our portfolio of services not only improves patient convenience but also represents a step forward in making innovative treatments more accessible in China and in the 75 other countries where Marken provides home healthcare and direct-to-and-from patient logistics services.  

Marken’s initiative in China exemplifies our vision for the future of healthcare — one where patient needs and access to quality care lead the way. This milestone is just one of many, as we continue to explore and implement innovative healthcare solutions globally.